Cargando…
A Phase I/III, multicenter, open-label trial of talimogene laherparepvec (T-VEC) in combination with pembrolizumab for the treatment of unresected, stage IIIb-IV melanoma (MASTERKEY-265)
Autores principales: | Long, Georgina V, Dummer, Reinhard, Ribas, Antoni, Puzanov, Igor, Michielin, Olivier, VanderWalde, Ari, Andtbacka, Robert HI, Cebon, Jonathan, Fernandez, Eugenio, Malvehy, Josep, Olszanski, Anthony J, Gajewski, Thomas F, Kirkwood, John M, Kuznetsova, Olga, Chen, Lisa, Kaufman, David R, Chou, Jeffrey, Hodi, F Stephen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4645515/ http://dx.doi.org/10.1186/2051-1426-3-S2-P181 |
Ejemplares similares
-
Phase 1 results of a phase 1b/2, multicenter, open-label trial to evaluate safety and efficacy of talimogene laherparepvec (T-VEC) and ipilimumab (ipi) vs ipi alone in previously untreated, unresected stage IIIB-IV melanoma
por: Puzanov, Igor, et al.
Publicado: (2013) -
Association between durable response (DR) and overall survival (OS) in patients with unresected stage IIIb-IV melanoma treated with Talimogene Laherparepvec (T-VEC) in the Phase III OPTiM trial
por: Kaufman, Howard L, et al.
Publicado: (2014) -
A practical guide to the handling and administration of talimogene laherparepvec in Europe
por: Harrington, Kevin J, et al.
Publicado: (2017) -
Talimogene Laherparepvec (T-VEC): An Intralesional Cancer Immunotherapy for Advanced Melanoma
por: Ferrucci, Pier Francesco, et al.
Publicado: (2021) -
Patterns of Clinical Response with Talimogene Laherparepvec (T-VEC) in Patients with Melanoma Treated in the OPTiM Phase III Clinical Trial
por: Andtbacka, Robert H. I., et al.
Publicado: (2016)